Ri-Fang Yang
Research Subjects
Ri-Fang Yang has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Rui Song
Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
6 shared publicationsHong-Xia Chen
Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
5 shared publicationsLiu-Hong Yun
5 shared publicationsNan Zhao
Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
5 shared publications- Wenxia Zhou
State Key Laboratory of National Security Specially Needed Medicines, Academy of Military Medical Sciences, Beijing 100850, China
5 shared publications You-Zhi Zhang
Department of New Drug Evaluation, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
5 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 743, 126-132
A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats
- 1 November 2014
- Published by Elsevier in European Journal of Pharmacology
- Vol. 743, 126-132
A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats
- 1 June 2014
- Published by Elsevier in Neuropharmacology
- Vol. 81, 116-125
Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa)
- 1 June 2014
- Published by Elsevier in Neuropharmacology
- Vol. 81, 116-125
Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa)
- Open Access
- 24 April 2014
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 17 (10) , 1659-1669
Anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder
Recently, the translocator protein (18 kDa) (TSPO), previously called peripheral benzodiazepine receptor (PBR) and both the starting point and an impo
- 24 April 2014
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 17 (10) , 1659-1669
Open AccessAnxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in animal models of post-traumatic stress disorder
Recently, the translocator protein (18 kDa) (TSPO), previously called peripheral benzodiazepine receptor (PBR) and both the starting point and an impo
- 1 February 2014
- Published by Elsevier in Neuropharmacology
- Vol. 77, 398-405
Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats
- 1 February 2014
- Published by Elsevier in Neuropharmacology
- Vol. 77, 398-405
Blockade of D3 receptors by YQA14 inhibits cocaine's rewarding effects and relapse to drug-seeking behavior in rats
- RetractedOpen Access
- 18 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83271
Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist
It has been suggested that drugs combining activities of selective serotonin reuptake inhibitor and 5-HT1A receptor agonist may form a novel strategy for higher therapeutic efficacy of antidepressant. The present study aimed to examine the pharmacology of YL-0919, a novel synthetic compound with combined high affinity and selectivity for serotonin transporter and 5-HT1A receptors. We performed in vitro binding and function assays and in vivo behavioral tests to assess the pharmacological properties and antidepressant-like efficacy of YL-0919. YL-0919 displayed high affinity in vitro to both 5-HT1A receptor and 5-HT transporter prepared from rat cortical tissue. It exerted an inhibitory effect on forskolin-stimulated cAMP formation and potently inhibited 5-HT uptake in both rat cortical synaptosomes and recombinant cells. After acute p.o. administration, very low doses of YL-0919 reduced the immobility time in tail suspension test and forced swimming test in mice and rats, with no significant effect on locomotor activity in open field test. Furthermore, WAY-100635 (a selective 5-HT1A receptor antagonist, 0.3 mg/kg) significantly blocked the effect of YL-0919 in tail suspension test and forced swimming test. In addition, chronic YL-0919 treatment significantly reversed the depressive-like behaviors in chronically stressed rats. These findings suggest that YL-0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-HT1A receptor agonist and 5-HT uptake blocker, showing remarkable antidepressant effects in animal models. Therefore, YL-0919 may be used as a new option for the treatment of major depressive disorder.
- 18 December 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83271
RetractedOpen AccessAntidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist
It has been suggested that drugs combining activities of selective serotonin reuptake inhibitor and 5-HT1A receptor agonist may form a novel strategy for higher therapeutic efficacy of antidepressant. The present study aimed to examine the pharmacology of YL-0919, a novel synthetic compound with combined high affinity and selectivity for serotonin transporter and 5-HT1A receptors. We performed in vitro binding and function assays and in vivo behavioral tests to assess the pharmacological properties and antidepressant-like efficacy of YL-0919. YL-0919 displayed high affinity in vitro to both 5-HT1A receptor and 5-HT transporter prepared from rat cortical tissue. It exerted an inhibitory effect on forskolin-stimulated cAMP formation and potently inhibited 5-HT uptake in both rat cortical synaptosomes and recombinant cells. After acute p.o. administration, very low doses of YL-0919 reduced the immobility time in tail suspension test and forced swimming test in mice and rats, with no significant effect on locomotor activity in open field test. Furthermore, WAY-100635 (a selective 5-HT1A receptor antagonist, 0.3 mg/kg) significantly blocked the effect of YL-0919 in tail suspension test and forced swimming test. In addition, chronic YL-0919 treatment significantly reversed the depressive-like behaviors in chronically stressed rats. These findings suggest that YL-0919, a novel structure compound, exerts dual effect on the serotonergic system, as both 5-HT1A receptor agonist and 5-HT uptake blocker, showing remarkable antidepressant effects in animal models. Therefore, YL-0919 may be used as a new option for the treatment of major depressive disorder.
- 15 November 2013
- Vol. 720, 212-7
The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-prime reactivation of morphine-induced conditioned place preference in rats.
Increasing evidence suggests that the mesolimbic dopamine system plays a critical role in opioid addiction. However, there is currently no standard drug treatment for opioid addiction. Growing preclinical evidence indicates that the dopamine D(3) receptor antagonists are the potential anti-addiction pharmacotherapeutic agents based on animal models of multiple drug addiction. In this study, we investigated the inhibitory effects of YQA14, a novel dopamine D(3) receptor antagonist with a high affinity and selectivity for dopamine D(3) receptor, using morphine-induced conditioned place preference (CPP) in rats. The results suggested that YQA14 (6.25-25 mg/kg; intraperitoneal, i.p.) decreased the expression of morphine (10 mg/kg, s.c.)-induced CPP in a dose-related manner but did not influence the acquisition of morphine-induced CPP. At a 25 mg/kg dose of YQA14, it also notably inhibited the reactivation of morphine-priming CPP. These findings suggest that YQA14 is a potential agent for anti-opioid addiction which warrants further study and development.
- 15 November 2013
- Vol. 720, 212-7
The dopamine D(3) receptor antagonist YQA14 that inhibits the expression and drug-prime reactivation of morphine-induced conditioned place preference in rats.
Increasing evidence suggests that the mesolimbic dopamine system plays a critical role in opioid addiction. However, there is currently no standard drug treatment for opioid addiction. Growing preclinical evidence indicates that the dopamine D(3) receptor antagonists are the potential anti-addiction pharmacotherapeutic agents based on animal models of multiple drug addiction. In this study, we investigated the inhibitory effects of YQA14, a novel dopamine D(3) receptor antagonist with a high affinity and selectivity for dopamine D(3) receptor, using morphine-induced conditioned place preference (CPP) in rats. The results suggested that YQA14 (6.25-25 mg/kg; intraperitoneal, i.p.) decreased the expression of morphine (10 mg/kg, s.c.)-induced CPP in a dose-related manner but did not influence the acquisition of morphine-induced CPP. At a 25 mg/kg dose of YQA14, it also notably inhibited the reactivation of morphine-priming CPP. These findings suggest that YQA14 is a potential agent for anti-opioid addiction which warrants further study and development.
- 1 November 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 720 (1-3) , 212-217
The dopamine D3 receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats
- 1 November 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 720 (1-3) , 212-217
The dopamine D3 receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats
- 1 September 2013
- Published by Elsevier in Neuropharmacology
- Vol. 72, 82-87
Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice
- 1 September 2013
- Published by Elsevier in Neuropharmacology
- Vol. 72, 82-87
Dopamine D3 receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice